Lincoln Pharmaceuticals Limited

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SUNPHARMA.BO has a market cap of 4.1T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SUNPHARMA.BO trades at ₹1,694.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SUNPHARMA.BO's P/E ratio is 37.25. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, LINCOLN.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check SUNPHARMA.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SUNPHARMA.NS has a market cap of 4.1T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SUNPHARMA.NS trades at ₹1,693.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SUNPHARMA.NS's P/E ratio is 37.17. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, LINCOLN.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check SUNPHARMA.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, DIVISLAB.BO has a market cap of 1.6T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while DIVISLAB.BO trades at ₹5,857.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas DIVISLAB.BO's P/E ratio is 62.74. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, LINCOLN.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check DIVISLAB.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, DIVISLAB.NS has a market cap of 1.6T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while DIVISLAB.NS trades at ₹5,856.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas DIVISLAB.NS's P/E ratio is 62.72. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, LINCOLN.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check DIVISLAB.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while TORNTPHARM.BO trades at ₹3,989.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas TORNTPHARM.BO's P/E ratio is 63.07. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, LINCOLN.NS is less volatile compared to TORNTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check TORNTPHARM.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, TORNTPHARM.NS has a market cap of 1.3T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while TORNTPHARM.NS trades at ₹3,987.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas TORNTPHARM.NS's P/E ratio is 59.50. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, LINCOLN.NS is less volatile compared to TORNTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check TORNTPHARM.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while LUPIN.BO trades at ₹2,276.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas LUPIN.BO's P/E ratio is 24.13. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, LINCOLN.NS is less volatile compared to LUPIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check LUPIN.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while LUPIN.NS trades at ₹2,274.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas LUPIN.NS's P/E ratio is 22.44. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, LINCOLN.NS is less volatile compared to LUPIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check LUPIN.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, DRREDDY.BO has a market cap of 1T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while DRREDDY.BO trades at ₹1,217.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas DRREDDY.BO's P/E ratio is 17.95. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, LINCOLN.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check DRREDDY.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, DRREDDY.NS has a market cap of 1T. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while DRREDDY.NS trades at ₹1,217.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas DRREDDY.NS's P/E ratio is 17.94. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, LINCOLN.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check DRREDDY.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ZYDUSLIFE.BO has a market cap of 869.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ZYDUSLIFE.BO trades at ₹864.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ZYDUSLIFE.BO's P/E ratio is 17.62. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ZYDUSLIFE.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ZYDUSLIFE.NS has a market cap of 869.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ZYDUSLIFE.NS trades at ₹864.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ZYDUSLIFE.NS's P/E ratio is 17.63. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ZYDUSLIFE.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, MANKIND.NS has a market cap of 825B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while MANKIND.NS trades at ₹1,998.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas MANKIND.NS's P/E ratio is 46.23. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, LINCOLN.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check MANKIND.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, MANKIND.BO has a market cap of 824.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while MANKIND.BO trades at ₹1,997.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas MANKIND.BO's P/E ratio is 46.22. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, LINCOLN.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check MANKIND.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AUROPHARMA.BO has a market cap of 775.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AUROPHARMA.BO trades at ₹1,335.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AUROPHARMA.BO's P/E ratio is 22.69. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, LINCOLN.NS is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check AUROPHARMA.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AUROPHARMA.NS has a market cap of 774.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AUROPHARMA.NS trades at ₹1,333.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AUROPHARMA.NS's P/E ratio is 22.22. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, LINCOLN.NS is less volatile compared to AUROPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check AUROPHARMA.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ALKEM.NS has a market cap of 628.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ALKEM.NS trades at ₹5,258.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ALKEM.NS's P/E ratio is 26.53. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ALKEM.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ALKEM.BO has a market cap of 628.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ALKEM.BO trades at ₹5,257.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ALKEM.BO's P/E ratio is 26.51. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ALKEM.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GLENMARK.BO has a market cap of 591B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GLENMARK.BO trades at ₹2,094.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GLENMARK.BO's P/E ratio is 55.55. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check GLENMARK.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GLENMARK.NS has a market cap of 590.3B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GLENMARK.NS trades at ₹2,091.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GLENMARK.NS's P/E ratio is 55.56. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check GLENMARK.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, LAURUSLABS.BO has a market cap of 563.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while LAURUSLABS.BO trades at ₹1,044.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas LAURUSLABS.BO's P/E ratio is 67.11. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, LINCOLN.NS is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check LAURUSLABS.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, LAURUSLABS.NS has a market cap of 563B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while LAURUSLABS.NS trades at ₹1,042.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas LAURUSLABS.NS's P/E ratio is 66.68. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, LINCOLN.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check LAURUSLABS.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, LINCOLN.NS is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check SUVENPHAR.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, LINCOLN.NS is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check SUVENPHAR.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, IPCALAB.NS has a market cap of 377.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while IPCALAB.NS trades at ₹1,488.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas IPCALAB.NS's P/E ratio is 41.46. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check IPCALAB.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, IPCALAB.BO has a market cap of 377B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while IPCALAB.BO trades at ₹1,485.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas IPCALAB.BO's P/E ratio is 41.50. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check IPCALAB.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AJANTPHARM.BO has a market cap of 349.2B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AJANTPHARM.BO trades at ₹2,795.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AJANTPHARM.BO's P/E ratio is 34.46. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, LINCOLN.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check AJANTPHARM.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AJANTPHARM.NS has a market cap of 348.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AJANTPHARM.NS trades at ₹2,791.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AJANTPHARM.NS's P/E ratio is 34.41. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, LINCOLN.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check AJANTPHARM.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, JBCHEPHARM.NS has a market cap of 314.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while JBCHEPHARM.NS trades at ₹1,961.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas JBCHEPHARM.NS's P/E ratio is 42.37. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, LINCOLN.NS is less volatile compared to JBCHEPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check JBCHEPHARM.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, JBCHEPHARM.BO has a market cap of 314.1B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while JBCHEPHARM.BO trades at ₹1,956.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas JBCHEPHARM.BO's P/E ratio is 41.15. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, LINCOLN.NS is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check JBCHEPHARM.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, EMCURE.NS has a market cap of 293.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while EMCURE.NS trades at ₹1,547.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas EMCURE.NS's P/E ratio is 33.68. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, LINCOLN.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check EMCURE.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, LINCOLN.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check PEL.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, WOCKPHARMA.BO has a market cap of 206.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while WOCKPHARMA.BO trades at ₹1,272.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas WOCKPHARMA.BO's P/E ratio is 1001.65. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, LINCOLN.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check WOCKPHARMA.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, WOCKPHARMA.NS has a market cap of 206.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while WOCKPHARMA.NS trades at ₹1,271.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas WOCKPHARMA.NS's P/E ratio is 1001.18. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, LINCOLN.NS is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check WOCKPHARMA.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ASTRAZEN.NS has a market cap of 195.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ASTRAZEN.NS trades at ₹7,827.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ASTRAZEN.NS's P/E ratio is 97.87. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ASTRAZEN.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ASTRAZEN.BO has a market cap of 195.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ASTRAZEN.BO trades at ₹7,817.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ASTRAZEN.BO's P/E ratio is 96.87. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ASTRAZEN.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, PPLPHARMA.BO has a market cap of 188B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while PPLPHARMA.BO trades at ₹142.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas PPLPHARMA.BO's P/E ratio is -114.56. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, LINCOLN.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check PPLPHARMA.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ERIS.NS has a market cap of 184.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ERIS.NS trades at ₹1,332.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ERIS.NS's P/E ratio is 42.26. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ERIS.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ERIS.BO has a market cap of 184.3B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ERIS.BO trades at ₹1,330.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ERIS.BO's P/E ratio is 42.08. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ERIS.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, NATCOPHARM.BO has a market cap of 184.1B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while NATCOPHARM.BO trades at ₹1,027.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas NATCOPHARM.BO's P/E ratio is 11.96. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, LINCOLN.NS is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check NATCOPHARM.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, NATCOPHARM.NS has a market cap of 184B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while NATCOPHARM.NS trades at ₹1,027.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas NATCOPHARM.NS's P/E ratio is 11.82. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, LINCOLN.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check NATCOPHARM.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, NEULANDLAB.BO has a market cap of 159.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while NEULANDLAB.BO trades at ₹12,434.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas NEULANDLAB.BO's P/E ratio is 88.87. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check NEULANDLAB.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, NEULANDLAB.NS has a market cap of 159.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while NEULANDLAB.NS trades at ₹12,433.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas NEULANDLAB.NS's P/E ratio is 88.81. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check NEULANDLAB.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GRANULES.BO has a market cap of 149B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GRANULES.BO trades at ₹614.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GRANULES.BO's P/E ratio is 27.30. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, LINCOLN.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check GRANULES.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GRANULES.NS has a market cap of 148.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GRANULES.NS trades at ₹613.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GRANULES.NS's P/E ratio is 27.25. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, LINCOLN.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check GRANULES.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, LINCOLN.NS is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check GLS.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, LINCOLN.NS is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check GLS.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, JUBLPHARMA.BO has a market cap of 133B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while JUBLPHARMA.BO trades at ₹839.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas JUBLPHARMA.BO's P/E ratio is 30.79. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, LINCOLN.NS is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check JUBLPHARMA.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, JUBLPHARMA.NS has a market cap of 132.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while JUBLPHARMA.NS trades at ₹839.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas JUBLPHARMA.NS's P/E ratio is 30.77. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, LINCOLN.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check JUBLPHARMA.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, APLLTD.NS has a market cap of 129B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while APLLTD.NS trades at ₹656.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas APLLTD.NS's P/E ratio is 20.45. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check APLLTD.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, APLLTD.BO has a market cap of 128.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while APLLTD.BO trades at ₹655.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas APLLTD.BO's P/E ratio is 20.47. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check APLLTD.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ALIVUS.NS has a market cap of 121.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ALIVUS.NS trades at ₹989.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ALIVUS.NS's P/E ratio is 22.39. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, LINCOLN.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check ALIVUS.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ALIVUS.BO has a market cap of 121.2B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ALIVUS.BO trades at ₹987.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ALIVUS.BO's P/E ratio is 22.34. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, LINCOLN.NS is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check ALIVUS.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, CAPLIPOINT.BO has a market cap of 119.2B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while CAPLIPOINT.BO trades at ₹1,567.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas CAPLIPOINT.BO's P/E ratio is 19.46. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, LINCOLN.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check CAPLIPOINT.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, CAPLIPOINT.NS has a market cap of 119B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while CAPLIPOINT.NS trades at ₹1,565.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas CAPLIPOINT.NS's P/E ratio is 19.44. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, LINCOLN.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check CAPLIPOINT.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, COHANCE.BO has a market cap of 117.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while COHANCE.BO trades at ₹307.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas COHANCE.BO's P/E ratio is 60.66. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, LINCOLN.NS is more volatile compared to COHANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check COHANCE.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, COHANCE.NS has a market cap of 117.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while COHANCE.NS trades at ₹307.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas COHANCE.NS's P/E ratio is 60.72. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, LINCOLN.NS is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check COHANCE.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, LINCOLN.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check CAPPL.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, STAR.NS has a market cap of 89.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while STAR.NS trades at ₹971.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas STAR.NS's P/E ratio is 17.50. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, LINCOLN.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check STAR.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, STAR.BO has a market cap of 89.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while STAR.BO trades at ₹969.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas STAR.BO's P/E ratio is 17.47. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, LINCOLN.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check STAR.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, VIYASH.NS has a market cap of 83.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while VIYASH.NS trades at ₹191.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas VIYASH.NS's P/E ratio is 74.04. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, LINCOLN.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check VIYASH.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, PGHL.NS has a market cap of 79.3B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while PGHL.NS trades at ₹4,778.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas PGHL.NS's P/E ratio is 33.53. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, LINCOLN.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check PGHL.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, PGHL.BO has a market cap of 79.2B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while PGHL.BO trades at ₹4,770.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas PGHL.BO's P/E ratio is 33.48. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, LINCOLN.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check PGHL.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AKUMS.NS has a market cap of 76.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AKUMS.NS trades at ₹499.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AKUMS.NS's P/E ratio is 23.88. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, LINCOLN.NS is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check AKUMS.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SHILPAMED.NS has a market cap of 76.1B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SHILPAMED.NS trades at ₹388.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SHILPAMED.NS's P/E ratio is 34.42. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, LINCOLN.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check SHILPAMED.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SUDEEPPHRM.NS has a market cap of 69.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SUDEEPPHRM.NS trades at ₹615.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SUDEEPPHRM.NS's P/E ratio is 41.39. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, LINCOLN.NS is more volatile compared to SUDEEPPHRM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check SUDEEPPHRM.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AARTIPHARM.BO has a market cap of 58.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AARTIPHARM.BO trades at ₹645.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AARTIPHARM.BO's P/E ratio is 27.43. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, LINCOLN.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check AARTIPHARM.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AARTIPHARM.NS has a market cap of 58.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AARTIPHARM.NS trades at ₹645.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AARTIPHARM.NS's P/E ratio is 27.40. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, LINCOLN.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check AARTIPHARM.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, FDC.BO has a market cap of 54.3B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while FDC.BO trades at ₹333.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas FDC.BO's P/E ratio is 25.06. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, LINCOLN.NS is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check FDC.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, FDC.NS has a market cap of 54.3B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while FDC.NS trades at ₹333.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas FDC.NS's P/E ratio is 25.06. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, LINCOLN.NS is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check FDC.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, LINCOLN.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check SEQUENT.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, LINCOLN.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check SEQUENT.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SPARC.BO has a market cap of 40.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SPARC.BO trades at ₹124.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SPARC.BO's P/E ratio is -15.06. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, LINCOLN.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check SPARC.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, INNOVACAP.NS has a market cap of 40.3B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while INNOVACAP.NS trades at ₹704.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas INNOVACAP.NS's P/E ratio is 30.49. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, LINCOLN.NS is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check INNOVACAP.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SPARC.NS has a market cap of 40.3B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SPARC.NS trades at ₹124.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SPARC.NS's P/E ratio is -15.02. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, LINCOLN.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check SPARC.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SHILPAMED.BO has a market cap of 38B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SHILPAMED.BO trades at ₹388.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SHILPAMED.BO's P/E ratio is 34.40. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, LINCOLN.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check SHILPAMED.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SUVEN.NS has a market cap of 36.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SUVEN.NS trades at ₹157.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SUVEN.NS's P/E ratio is -12.81. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, LINCOLN.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check SUVEN.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SUVEN.BO has a market cap of 36.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SUVEN.BO trades at ₹157.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SUVEN.BO's P/E ratio is -12.79. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, LINCOLN.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check SUVEN.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AARTIDRUGS.NS has a market cap of 32.2B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AARTIDRUGS.NS trades at ₹352.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AARTIDRUGS.NS's P/E ratio is 15.96. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, LINCOLN.NS is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check AARTIDRUGS.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, AARTIDRUGS.BO has a market cap of 32.1B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while AARTIDRUGS.BO trades at ₹352.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas AARTIDRUGS.BO's P/E ratio is 15.92. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, LINCOLN.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check AARTIDRUGS.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, RPGLIFE.BO has a market cap of 31.8B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while RPGLIFE.BO trades at ₹1,922.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas RPGLIFE.BO's P/E ratio is 15.70. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, LINCOLN.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check RPGLIFE.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, RPGLIFE.NS has a market cap of 31.8B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while RPGLIFE.NS trades at ₹1,921.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas RPGLIFE.NS's P/E ratio is 15.67. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, LINCOLN.NS is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check RPGLIFE.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GUFICBIO.BO has a market cap of 29.1B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GUFICBIO.BO trades at ₹289.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GUFICBIO.BO's P/E ratio is 57.95. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, LINCOLN.NS is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check GUFICBIO.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GUFICBIO.NS has a market cap of 28.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GUFICBIO.NS trades at ₹288.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GUFICBIO.NS's P/E ratio is 57.95. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, LINCOLN.NS is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check GUFICBIO.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, GUJTHEM.NS has a market cap of 27.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while GUJTHEM.NS trades at ₹251.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas GUJTHEM.NS's P/E ratio is 57.38. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, LINCOLN.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check GUJTHEM.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ORCHPHARMA.NS has a market cap of 26.6B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ORCHPHARMA.NS trades at ₹523.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ORCHPHARMA.NS's P/E ratio is 140.05. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, LINCOLN.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check ORCHPHARMA.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ORCHPHARMA.BO has a market cap of 26.5B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ORCHPHARMA.BO trades at ₹522.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ORCHPHARMA.BO's P/E ratio is 138.86. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, LINCOLN.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check ORCHPHARMA.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, NOVARTIND.BO has a market cap of 25.4B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while NOVARTIND.BO trades at ₹1,027.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas NOVARTIND.BO's P/E ratio is 25.77. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, LINCOLN.NS is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check NOVARTIND.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, BLISSGVS.BO has a market cap of 24.8B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while BLISSGVS.BO trades at ₹234.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas BLISSGVS.BO's P/E ratio is 23.04. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, LINCOLN.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check BLISSGVS.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, BLISSGVS.NS has a market cap of 24.8B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while BLISSGVS.NS trades at ₹234.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas BLISSGVS.NS's P/E ratio is 22.98. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, LINCOLN.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check BLISSGVS.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SOLARA.NS has a market cap of 22.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SOLARA.NS trades at ₹476.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SOLARA.NS's P/E ratio is -98.98. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, LINCOLN.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check SOLARA.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, SOLARA.BO has a market cap of 22.9B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while SOLARA.BO trades at ₹475.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas SOLARA.BO's P/E ratio is -99.20. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, LINCOLN.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check SOLARA.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, IOLCP.BO has a market cap of 22.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while IOLCP.BO trades at ₹77.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas IOLCP.BO's P/E ratio is 19.58. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, LINCOLN.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check IOLCP.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, IOLCP.NS has a market cap of 22.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while IOLCP.NS trades at ₹77.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas IOLCP.NS's P/E ratio is 19.57. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, LINCOLN.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check IOLCP.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, UNICHEMLAB.BO has a market cap of 21B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while UNICHEMLAB.BO trades at ₹298.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas UNICHEMLAB.BO's P/E ratio is 7.14. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check UNICHEMLAB.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, UNICHEMLAB.NS has a market cap of 21B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while UNICHEMLAB.NS trades at ₹298.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas UNICHEMLAB.NS's P/E ratio is 7.14. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, LINCOLN.NS is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LINCOLN.NS.Check UNICHEMLAB.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, MOREPENLAB.BO has a market cap of 20.8B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while MOREPENLAB.BO trades at ₹37.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas MOREPENLAB.BO's P/E ratio is 21.22. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, LINCOLN.NS is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check MOREPENLAB.BO's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, MOREPENLAB.NS has a market cap of 20.7B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while MOREPENLAB.NS trades at ₹37.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas MOREPENLAB.NS's P/E ratio is 21.01. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, LINCOLN.NS is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check MOREPENLAB.NS's competition here

LINCOLN.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LINCOLN.NS stands at 12.1B. In comparison, ALEMBICLTD.NS has a market cap of 20B. Regarding current trading prices, LINCOLN.NS is priced at ₹604.90, while ALEMBICLTD.NS trades at ₹77.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LINCOLN.NS currently has a P/E ratio of 13.80, whereas ALEMBICLTD.NS's P/E ratio is 6.27. In terms of profitability, LINCOLN.NS's ROE is +0.13%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, LINCOLN.NS is less volatile compared to ALEMBICLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LINCOLN.NS.Check ALEMBICLTD.NS's competition here